PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000975836.58931.97 |
| _version_ | 1797280767868403712 |
|---|---|
| author | Antonio Salar Silvestre Judith Trotman Clementine Sarkozy Yuqin Song Laurie H. Sehn Loretta J. Nastoupil Wanhua Zhang Pierre Fustier Richard Delarue Pier Luigi Zinzani |
| author_facet | Antonio Salar Silvestre Judith Trotman Clementine Sarkozy Yuqin Song Laurie H. Sehn Loretta J. Nastoupil Wanhua Zhang Pierre Fustier Richard Delarue Pier Luigi Zinzani |
| author_sort | Antonio Salar Silvestre |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:45:58Z |
| format | Article |
| id | doaj.art-19348e008e05416db3510e8f5c9f1cfe |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:45:58Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-19348e008e05416db3510e8f5c9f1cfe2024-03-03T06:25:44ZengWileyHemaSphere2572-92412023-08-017e589319710.1097/01.HS9.0000975836.58931.97202308003-02133PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMAAntonio Salar Silvestre0Judith Trotman1Clementine Sarkozy2Yuqin Song3Laurie H. Sehn4Loretta J. Nastoupil5Wanhua Zhang6Pierre Fustier7Richard Delarue8Pier Luigi Zinzani91 Hospital del Mar, Barcelona, Spain2 Concord Repatriation General Hospital, University of Sydney, Concord, Australia3 Institut Curie, Paris, France4 Peking University Cancer Hospital and Institute, Beijing, China5 University of British Columbia, Vancouver, Canada6 MD Anderson Cancer Center, Houston, United States7 BeiGene USA, Inc., San Mateo, United States7 BeiGene USA, Inc., San Mateo, United States7 BeiGene USA, Inc., San Mateo, United States8 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italyhttp://journals.lww.com/10.1097/01.HS9.0000975836.58931.97 |
| spellingShingle | Antonio Salar Silvestre Judith Trotman Clementine Sarkozy Yuqin Song Laurie H. Sehn Loretta J. Nastoupil Wanhua Zhang Pierre Fustier Richard Delarue Pier Luigi Zinzani PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA HemaSphere |
| title | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_full | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_fullStr | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_full_unstemmed | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_short | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_sort | pb2276 mahogany a phase 3 trial of zanubrutinib plus anti cd20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma |
| url | http://journals.lww.com/10.1097/01.HS9.0000975836.58931.97 |
| work_keys_str_mv | AT antoniosalarsilvestre pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT judithtrotman pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT clementinesarkozy pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT yuqinsong pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT lauriehsehn pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT lorettajnastoupil pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT wanhuazhang pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT pierrefustier pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT richarddelarue pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT pierluigizinzani pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma |